EMBARK vs KAP
A side-by-side comparison of recorded mechanisms, evidence review status, related condition topics, and philosophical roots.
At a glance
Source checks, condition-specific assessments and expert review are separate steps. Each assessment applies only to its stated population and use. Topic links do not establish comparative effectiveness.
EMBARK
- Tradition
- Psychedelic
- Founder
- Brennan / Belser (2022)
- Review status
- Assessment not yet completed
- Focus
- Integration + Processing
- Format
- Individual (dyadic facilitation team)
- Duration
- Variable (structured phases: preparation, medicine sessions, integration)
KAP
- Tradition
- Psychedelic
- Founder
- Various (Wolfson, Bennett) (2010)
- Review status
- 7 source checks available
- Official sources
Guidelines and official sources (7)
6 clinical guideline checks · 1 regulatory source check
Read the recommendation and its scope. A source may discuss an approach without recommending it.
- SPRAVATO (esketamine) original prescribing information
Not a treatment recommendation
The historical drug indication is verified. It does not establish approval or guideline endorsement of KAP. This original label is not current prescribing information.
Scope: Esketamine nasal spray plus an oral antidepressant for adult TRD in 2019
- Management of Major Depressive Disorder
Discussed in the source
VA/DoD weakly suggests ketamine or esketamine augmentation. The recommendation concerns medication, not a named KAP psychotherapy protocol.
Scope: MDD after several adequate pharmacological trials have failed
- Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder
Discussed in the source
VA/DoD weakly recommends against ketamine for PTSD. The statement concerns medication and does not separately evaluate KAP.
Scope: Ketamine pharmacotherapy for adult PTSD; not a separate KAP psychotherapy assessment.
- Assessment and Management of Patients at Risk for Suicide
Discussed in the source
VA/DoD weakly supports ketamine infusion for short-term ideation reduction; evidence for preventing attempts or suicide is insufficient. KAP is not separately recommended.
Scope: Adjunctive ketamine infusion in adults aged 18 and over with major depression and suicidal ideation; medication rather than KAP psychotherapy.
- Management of Major Depressive Disorder
Discussed in the source
VA/DoD suggests against ketamine/esketamine as initial pharmacotherapy (weak against). Its separate augmentation recommendation concerns prior treatment failure; neither recommendation endorses a named KAP psychotherapy protocol.
Scope: Adults choosing initial medication treatment for MDD.
- Management of Bipolar Disorder
Discussed in the source
VA/DoD finds insufficient evidence for ketamine/esketamine alone or as adjuncts. The recommendation concerns medication and does not endorse KAP psychotherapy.
Scope: Adults with acute bipolar depression.
- Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder in Adults
Discussed in the source
APA reports insufficient evidence for ketamine in these comparisons. This is a drug-level finding, not a separate evaluation of the KAP psychotherapy protocol.
Scope: Adults with PTSD; ketamine compared with an active or inactive intervention.
- SPRAVATO (esketamine) original prescribing information
- Focus
- Experiential + Processing
- Format
- Individual
- Duration
- Short-medium
How they work
EMBARK
Core mechanism: Six domains the model holds to be common in psychedelic states organize preparation and integration; four 'care cornerstones' are meant to keep delivery ethical, trauma-informed, and culturally responsive. The structure organizes the therapy rather than explaining how psychedelics work.
Ontology: A whole person whose psychedelic experience activates multiple dimensions simultaneously (existential, somatic, relational, affective-cognitive) requiring a multi-domain therapeutic response rather than a single-mechanism model
KAP
Core mechanism: Ketamine's dissociative state, and the plasticity that follows it, are treated as a window for psychotherapeutic processing and new learning; the window is proposed rather than demonstrated
Ontology: Treatment-resistant conditions involve rigid neural patterns; ketamine disrupts rigidity and opens plasticity window
Related condition topics
These editorial cross-references organize reading. A shared link does not mean both approaches are effective, recommended, or interchangeable for that condition.
3 shared · 3 EMBARK-only · 1 KAP-only
Linked to both entries
Linked only in the EMBARK entry
Linked only in the KAP entry
What each assumes — and misses
EMBARK
Philosophical roots: Grof (non-ordinary states); James (varieties of religious experience); harm reduction philosophy; CBT, ACT, and psychodynamic traditions integrated
Blind spots: Developed within a pharmaceutical research context (Cybin); limited independent replication; open-source status means variable implementation quality; requires specialized training not yet standardized across programs
Therapeutic voice: You keep coming back to what your body was doing when it started. Let's stay there a while before we go to what it meant.
KAP
Philosophical roots: James (varieties of religious experience: altered states as data); Grof (non-ordinary states); Wolfson (ketamine as psychedelic medicine rather than anesthetic adjunct); neuroplasticity research
Blind spots: Regulatory fragmentation; limited standardization of psychotherapy component; risk of ketamine becoming the treatment rather than catalyst
Therapeutic voice: Last week you kept coming back to 'none of it is solid.' Let's stay there. What have you been treating as solid?
Choosing between them
EMBARK and KAP both sit within the Psychedelic tradition — they share a worldview about what suffering is and how change happens. Differences are more often about technique and emphasis than about underlying theory.
For deeper coverage: see the full EMBARK and KAP pages, or use the interactive comparison tool to add more modalities to this comparison.